Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-masked study of QL1205 versus Lucentis in wet age-related macular degeneration
2018-004486-13Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QL1205 in exudative macular degeneration (2 arms), sponsored by Qilu Pharmaceutical. Started Feb 2019; status: completed.
02
Drugs
QL1205
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2018-004486-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004486-13.